<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7122614/results/search/country/results.xml">
  <result pre="generated from groups actively monitoring the resistance among circulating strain—in" exact="the United States" post="this is actively done by the Centers for Diseases"/>
  <result pre="from groups actively monitoring the resistance among circulating strain—in the" exact="United States" post="this is actively done by the Centers for Diseases"/>
  <result pre="began to change when field isolates of A/H3N2 viruses from" exact="China" post="were noted to have a significant increase in the"/>
  <result pre="influenza season, approximately 70 % of the A/H3N2 isolates from" exact="China" post="and Hong Kong and nearly 15 % of those"/>
  <result pre="approximately 70 % of the A/H3N2 isolates from China and" exact="Hong Kong" post="and nearly 15 % of those from the United"/>
  <result pre="and Hong Kong and nearly 15 % of those from" exact="the United States" post="and Europe showed resistance due to a Ser31Asn mutation,"/>
  <result pre="Hong Kong and nearly 15 % of those from the" exact="United States" post="and Europe showed resistance due to a Ser31Asn mutation,"/>
  <result pre="mutation, and this frequency increased to over 90 % in" exact="the United States" post="during the 2005–2006 season [29, 38]. Since then, most"/>
  <result pre="and this frequency increased to over 90 % in the" exact="United States" post="during the 2005–2006 season [29, 38]. Since then, most"/>
  <result pre="tested by subtype No. (%) resistant Belshe et al. [24]" exact="United States" post="1978–1988 EIA, S 65 H1N1 0 181 H3N2 5"/>
  <result pre="0 181 H3N2 5 (2.0 %)a Valette et al. [202]" exact="France" post="1988–1990 EIA 28 H1N1 0 77 H3N2 0 Ziegler"/>
  <result pre="EIA, plaque 1813 28 (1.5 %) Suzuki et al. [205]" exact="Japan" post="1993–1998 Not stated 55 0 1999–2000 Not stated 179"/>
  <result pre="Not stated 179 6 (3.4 %) Shih et al. [206]" exact="Taiwan" post="1996–1998 Plaque, S 84 1(1.2 %) Bright et al."/>
  <result pre="1998–2004 589 H1N1 2 (0.3 %) Bright et al. [29]" exact="United States" post="2005 S 205 H3N2 193 (92.3 %) 8 H1N1"/>
  <result pre="%) 8 H1N1 2 (25 %) Saito et al. [207]" exact="Japan" post="2005–2006 S 354 H3N2 231 (65.3 %) 61 H1N1"/>
  <result pre="(65.3 %) 61 H1N1 0 Barr et al. [43] Australia," exact="New Zealand," post="Asia, South Africa 2005 S 102 H3N2 43 (42"/>
  <result pre="H1N1 0 Barr et al. [43] Australia, New Zealand, Asia," exact="South Africa" post="2005 S 102 H3N2 43 (42 %) 37 H1N1"/>
  <result pre="H3N2 viruses were 73.8 % in China, 69.6 % in" exact="Hong Kong," post="22.7 % in Taiwan, 15.1 % in South Korea,"/>
  <result pre="in Hong Kong, 22.7 % in Taiwan, 15.1 % in" exact="South Korea," post="4.3 % in Japan, 30.0 % in Canada, 19.2"/>
  <result pre="% in Canada, 19.2 % in Mexico, 14.5 % in" exact="United States," post="and 4.7 % in Europe The frequency of resistance"/>
  <result pre="initial human isolates of highly pathogenic avian A/H5N1 viruses in" exact="Hong Kong" post="in 1997 were M2 inhibitor susceptible, resistance to this"/>
  <result pre="since 1999, their use has been quite limited, except in" exact="Japan" post="and during the 2009 influenza A/H1N1 pandemic [88]. Clinical"/>
  <result pre="with an NA H275Y amino acid change emerged first in" exact="Norway" post="during the 2007–2008 season and was able to spread"/>
  <result pre="change in the low-pathogenic avian influenza A/H7N9 viruses circulating in" exact="China" post="since 2013 causes high NA inhibitor resistance to oseltamivir"/>
  <result pre="169 A/N2 0 128 B 0a Bovin and Goyette [217]" exact="Canada" post="1999–2000 NAI-CL 38 H3N2 0 40 H2N1 0 23"/>
  <result pre="B 2 (0.3 %) Asp198Glu, Ile222Thr Ferraris et al. [219]" exact="France" post="2002–2005 NAI-FA, S 788 H3N2 0b NISN WER [220]"/>
  <result pre="France 2002–2005 NAI-FA, S 788 H3N2 0b NISN WER [220]" exact="Japan" post="2003–2004 NAI-CL, S 1180 H3N2 3 (0.3 %) 2"/>
  <result pre="Glu119Val, 1 Arg292Lys 171 B 0 Hatakeyama et al. [221]" exact="Japan" post="2004–2005 NAI-FA, S 422 B 7 (1.7 %) 3"/>
  <result pre="%) 3 Asp198Asn, 3 Ile222Thr, 1 Ser250Gly NISN WER [222]" exact="Japan" post="2004–2005 NAI-CL, S 558 H3N2 0 4 His274Tyr 2005–2006"/>
  <result pre="understood at this point. The drug is currently licensed in" exact="Japan" post="for use selectively when approved by the Ministry of"/>
  <result pre="A20029921138495410.1073/pnas.21251969912368467 43.BarrIGet al.Increased adamantane resistance in influenza A(H3) viruses in" exact="Australia" post="and neighbouring countries in 2005Antiviral Res2007732112710.1016/j.antiviral.2006.08.00216963130 44.OhDYHurtACA review of"/>
  <result pre="porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in" exact="Germany" post="between 1981 and 2001Intervirology20064952869310.1159/00009424416809934 47.SleemanKet al.Antiviral susceptibility of variant"/>
  <result pre="47.SleemanKet al.Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in" exact="the United States" post="from 2011 to 2013Antimicrob Agents Chemother201458420455110.1128/AAC.02556-1324449767 48.JhungMAet al.Outbreak of"/>
  <result pre="al.Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the" exact="United States" post="from 2011 to 2013Antimicrob Agents Chemother201458420455110.1128/AAC.02556-1324449767 48.JhungMAet al.Outbreak of"/>
  <result pre="two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata," exact="Japan" post="and the clinical effectiveness of oseltamivir and zanamivirVirol J201075310.1186/1743-422X-7-5320202225"/>
  <result pre="influenza in AustraliaJ Infect Dis201220621485710.1093/infdis/jis33722561367 123.Okomo-AdhiamboMet al.Oseltamivir-resistant influenza A(H1N1)pdm09 viruses," exact="United States," post="2013–14Emerg Infect Dis20152111364110.3201/eid2101.14100625532050 124.TakashitaEet al.A community cluster of influenza"/>
  <result pre="experience with intravenous zanamivir under an Emergency IND program in" exact="the United States" post="(2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to"/>
  <result pre="with intravenous zanamivir under an Emergency IND program in the" exact="United States" post="(2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to"/>
  <result pre="hemagglutininsScience20113336044850610.1126/science.120566921798894 198.Okomo-AdhiamboMet al.Drug susceptibility surveillance of influenza viruses circulating in" exact="the United States" post="in 2011-2012: application of the WHO antiviral working group"/>
  <result pre="198.Okomo-AdhiamboMet al.Drug susceptibility surveillance of influenza viruses circulating in the" exact="United States" post="in 2011-2012: application of the WHO antiviral working group"/>
  <result pre="trialJAMA200128567485410.1001/jama.285.6.74811176912 212.GalbraithAWet al.Study of 1-adamantanamine hydrochloride used prophylactically during the" exact="Hong Kong" post="influenza epidemic in the family environmentBull World Health Organ1969413677824908342"/>
  <result pre="zanamivir and oseltamivir: a study performed on viruses circulating in" exact="France" post="prior to the introduction of neuraminidase inhibitors in clinical"/>
  <result pre="of neuraminidase inhibitor resistance among clinical influenza virus isolates in" exact="Japan" post="during the 2003-2006 influenza seasons. Wkly Epidemiol Rec, 2007."/>
 </snippets>
</snippetsTree>
